“No new adverse reactions other than those described in the instructions (short-term soreness at the injection site, a slight increase in temperature) have been identified,” RIA Novosti Maksyutov quotes.
The head of Vector also spoke about the features of revaccination with EpiVacCorona.
Earlier it was reported that the first batch of the EpiVacCorona vaccine, developed by the Vector Scientific Center for Virology and Biotechnology, was sent to 40 regions of Russia.